Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Multiple myeloma is a malignant incurable hematological disease where survival has been
significantly improved by high-dose melphalan with autologous stem cell support (ASCT) in
younger patients. However, the disease will eventually relapse and new treatment is demanded.
Bortezomib is a newly approved drug for treating relapsing multiple myeloma. It has a
different biological effect and response even in patients refractory to conventional
chemotherapy. The purpose of the study is in a randomized design to investigate if addition
of bortezomib by 20 injections during a 4 months period starting 3 month after ASCT can
prolong the time to progression compared to patients receiving no consolidation or
maintenance therapy.